GGrantIndex
← Leaderboards

Robert N Golden

University Of North Carolina Chapel Hill

$31,944,665
Attributed
$31,944,665
Total exposure
9
Grants
3
Lead (contact PI)

Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).

Funding over time

peak $14.9M · FY200523
$20M$15M$10M$5M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23

Funding mix

By agency

NIH$40,934,547 · 11

By mechanism

C06$36,873,525 · 4
M01$4,061,022 · 7

Top collaborators

No co-investigators on record.

Most similar at University Of North Carolina Chapel Hill

Same institution · by research overlap

Others in their field

Top investigators on “Clinical Research

Research focus

Clinical ResearchHuman SubjectHuman Therapy EvaluationMental Disorder ChemotherapyClinical DepressionDrug Screening /EvaluationSertralineChromiumCombination ChemotherapyDrug InteractionsClinical Trial Phase IDrug MetabolismBupropionPsychiatryHiv InfectionsPsychologyCase HistoryNeuropsychologyCopingMental Health EpidemiologyNervous System Disorder EpidemiologyOutcomes ResearchPatient Oriented ResearchMajor Depression

Grant awards (28)

A National, Theranostic Cyclotron Resource to Drive Fundamental and Translational Medical Science$8,000,000
C06 · FY2023 · OD · contact PI
Cardiovascular and Regenerative Sciences in WIMR Phase II$14,873,525
C06 · FY2010 · RR · contact PI
General Clinical Research Center$210,004
M01 · FY2007 · RR · contact PI
General Clinical Research Center$1,779,878
M01 · FY2006 · RR · contact PI
NIMH HUMAN GENETICS INITIATION$248
M01 · FY2006 · RR · contact PI
NIMH HUMAN GENETICS INITIATION$22,933
M01 · FY2005 · RR
EXTRAMURAL FACILITIES IMPROVEMENT PROGRAM$7,000,000
C06 · FY2004 · RR
NIMH Human Genetics Initiation$17,548
M01 · FY2004 · RR
Chromium Potentiation of Sertraline in Refractory Mood Disorders$1,981
M01 · FY2004 · RR
The Neurogenetics of Serotonin in Depression$283
M01 · FY2004 · RR
EXTRAMURAL FACILITIES IMPROVED PROGRAM PROJECTS$7,000,000
C06 · FY2003 · RR
COPING IN HEALTH AND ILLNESS PROJECT$190,747
M01 · FY2002 · RR
BUPROPION SR IN ATYPICAL DEPRESSION$190,747
M01 · FY2002 · RR
CHROMIUM POTENTIATION OF SERTRALINE IN REFRACTORY DYSTHYMIC DISORDER$190,747
M01 · FY2002 · RR
BUPROPION SR IN ATYPICAL DEPRESSION$294,555
M01 · FY2001 · RR
COPING IN HEALTH AND ILLNESS PROJECT$294,555
M01 · FY2001 · RR
CHROMIUM POTENTIATION OF SERTRALINE IN REFRACTORY DYSTHYMIC DISORDER$294,555
M01 · FY2001 · RR
COPING IN HEALTH AND ILLNESS PROJECT$190,747
M01 · FY2001 · RR
BUPROPION SR IN ATYPICAL DEPRESSION$190,747
M01 · FY2001 · RR
CHROMIUM POTENTIATION OF SERTRALINE IN REFRACTORY DYSTHYMIC DISORDER$190,747
M01 · FY2001 · RR
CHROMIUM POTENTIATION OF SERTRALINE IN REFRACTORY DYSTHYMIC DISORDER$0
M01 · FY2000 · RR
CHROMIUM POTENTIATION OF SERTRALINE IN REFRACTORY DYSTHYMIC DISORDER$0
M01 · FY2000 · RR
EFFICACY OF PREGABALIN IN PATIENTS WITH SOCIAL PHOBIA$0
M01 · FY2000 · RR
CHROMIUM POTENTIATION OF SERTRALINE IN REFRACTORY DYSTHYMIC DISORDER$0
M01 · FY2000 · RR
BUPROPION SR IN ATYPICAL DEPRESSION$0
M01 · FY2000 · RR
COPING IN HEALTH AND ILLNESS PROJECT$0
M01 · FY2000 · RR
EFFECSCY OF LU 26-054, CITALOPRAM IN MAJOR DEPRESSION$0
M01 · FY2000 · RR
CHROMIUM POTENTIATION OF SERTRALINE IN REFRACTORY DYSTHYMIC DISORDER$0
M01 · FY2000 · RR